ViaDerma, Inc. announced that the Company has begun sales and distribution of its highly anticipated topical antibiotic ointment. Its marketing, sales and distribution partner, Biogenx, Inc. has been preselling the product, under the name of VitaStem™. Which now retails for $79. The Company plans to start manufacturing the second production run of the product and now has streamlined the manufacturing. The Company expects to ramp up production, monthly as the interested in the product continues to grow. The Company will start production of its Patent Pending CBD or Cannabinoids product line. The Company would combine its two Patent pending technologies, the MMJ Patent #62466209, a patent for delivering medical marijuana /cannabis to the body by applying the medication onto the skin in an ointment base topical solution and the second Provisional patent # 62433964 for enhanced antibiotic and drug delivery for "Aqueous Topical Applications" for human and veterinarian uses. The Company would combine its proprietary solutions with CBD's and other natural products that treat psoriasis, fibromyalgia for pain and other ailments. The Company plans to continue to expand its (IP) "Intellectual Property Portfolio" in 2018. The company is ramping up sales and distribution and expect the orders to come in from several key countries abroad. The quick response by customers in all the testing trials have shown positive results and this has led to an overwhelming interest in its products in several markets around the world. This has opened the door for future products in several key markets. The contract manufacturer has now streamlined the process and has the capabilities to manufacture most of the products.